114 related articles for article (PubMed ID: 33404989)
21. Assessment of Micafungin Dosage Regimens in Patients with Cancer Using Pharmacokinetic/Pharmacodynamic Modeling and Monte Carlo Simulation.
Alqahtani S; Alfarhan A; Alsultan A; Alsarhani E; Alsubaie A; Asiri Y
Antibiotics (Basel); 2021 Nov; 10(11):. PubMed ID: 34827301
[TBL] [Abstract][Full Text] [Related]
22. Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials.
Kovanda LL; Walsh TJ; Benjamin DK; Arrieta A; Kaufman DA; Smith PB; Manzoni P; Desai AV; Kaibara A; Bonate PL; Hope WW
Pediatr Infect Dis J; 2018 Jun; 37(6):580-585. PubMed ID: 29762386
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics of micafungin in neonates and young infants.
Hope WW; Smith PB; Arrieta A; Buell DN; Roy M; Kaibara A; Walsh TJ; Cohen-Wolkowiez M; Benjamin DK
Antimicrob Agents Chemother; 2010 Jun; 54(6):2633-7. PubMed ID: 20308367
[TBL] [Abstract][Full Text] [Related]
24. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults.
Wasmann RE; Smit C; Ter Heine R; Koele SE; van Dongen EPH; Wiezer RMJ; Burger DM; Knibbe CAJ; Brüggemann RJM
J Antimicrob Chemother; 2019 Apr; 74(4):978-985. PubMed ID: 30649375
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic/pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in children, adolescents and adults by Monte Carlo simulation.
Xu G; Zhu L; Ge T; Liao S; Li N; Qi F
Int J Antimicrob Agents; 2016 Jun; 47(6):439-45. PubMed ID: 27179818
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation.
Zheng X; Xu G; Zhu L; Fang L; Zhang Y; Ding H; Tong Y; Sun J; Huang P
J Clin Pharmacol; 2018 Oct; 58(10):1266-1273. PubMed ID: 29762861
[TBL] [Abstract][Full Text] [Related]
28. Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.
Martial LC; Brüggemann RJ; Schouten JA; van Leeuwen HJ; van Zanten AR; de Lange DW; Muilwijk EW; Verweij PE; Burger DM; Aarnoutse RE; Pickkers P; Dorlo TP
Clin Pharmacokinet; 2016 Jun; 55(6):723-33. PubMed ID: 26649870
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis.
Dupont H; Massias L; Jung B; Ammenouche N; Montravers P
J Antimicrob Chemother; 2017 May; 72(5):1429-1432. PubMed ID: 28088767
[TBL] [Abstract][Full Text] [Related]
30. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei.
Shorr AF; Wu C; Kothari S
J Antimicrob Chemother; 2011 Feb; 66(2):375-80. PubMed ID: 21147825
[TBL] [Abstract][Full Text] [Related]
31. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
[TBL] [Abstract][Full Text] [Related]
32. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Killing Activity of Micafungin Against Six Candida Species Isolated from Peritoneal and Pleural Cavities in RPMI-1640, 10 and 30% Serum.
Tóth Z; Kardos T; Kovács R; Kardos G; Nagy F; Prépost E; Barta Z; Takacs I; Majoros L
Mycopathologia; 2018 Dec; 183(6):905-912. PubMed ID: 30382508
[TBL] [Abstract][Full Text] [Related]
34. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
36. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
37. Micafungin Population PK Analysis in Healthy and Septic Pigs: Can the Septic Porcine Model Predict the Micafungin PK in Septic Patients?
Garbez N; Mbatchi LC; Louart G; Wallis SC; Muller L; Lipman J; Roberts JA; Lefrant JY; Roger C
Pharm Res; 2021 Nov; 38(11):1863-1871. PubMed ID: 34845574
[TBL] [Abstract][Full Text] [Related]
38. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.
Conil JM; Georges B; Ravat F; Ruiz S; Seguin T; Metsu D; Fourcade O; Saivin S
Clin Ther; 2013 Oct; 35(10):1603-12. PubMed ID: 24094465
[TBL] [Abstract][Full Text] [Related]
39. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
Pfaller MA; Diekema DJ; Andes D; Arendrup MC; Brown SD; Lockhart SR; Motyl M; Perlin DS;
Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis.
Muilwijk EW; Maertens JA; van der Velden WJFM; Ter Heine R; Colbers A; Burger DM; Andes D; Theunissen K; Blijlevens NMA; Brüggemann RJM
J Antimicrob Chemother; 2018 Nov; 73(11):3095-3101. PubMed ID: 30137340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
